Adopting a functional precision medicine approach to reduce cancer disparities in Hispanic and Black children of Miami

采用功能性精准医学方法来减少迈阿密西班牙裔和黑人儿童的癌症差异

• 批准号: 10556509
• 负责人: Diana Azzam
• 金额: $ 35.4万
• 依托单位: FLORIDA INTERNATIONAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-20 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10556509
• 关键词: Address; Adopted; Adult; Advanced Malignant Neoplasm; Area; Biological Assay; Biology; Black Populations; Black race; Brain; Cancer Patient; Cause of Death; Central Nervous System Neoplasms; Child; Childhood; Childhood Cancer Treatment; Clinical; Clinical Management; Clinical Trials; Collaborations; Data; Detection; Diagnosis; Disease; Drug Combinations; Drug Screening; Enrollment; Ethnic Origin; FDA approved; Florida; Genetic; Genomics; Health Services Accessibility; Hispanic; Hispanic Populations; Hospitals; Individual; Inequality; Intervention; Label; Lead; Length; Libraries; Machine Learning; Malignant Childhood Neoplasm; Malignant Neoplasms; Medical center; Minority Groups; Minority-Serving Institution; Molecular; Molecular Genetics; Molecular Profiling; Mutation; Mutation Analysis; Not Hispanic or Latino; Oncology; Outcome; Patient-Focused Outcomes; Patients; Pediatric Hospitals; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Phenotype; Population; Positioning Attribute; Property; Race; Recommendation; Recurrence; Recurrent Malignant Neoplasm; Refractory; Relapse; Research; Research Project Grants; Testing; Time; Toxic effect; Treatment Efficacy; Tumor Tissue; United States; Work; actionable mutation; anticancer research; base; cancer health disparity; cancer survival; cancer therapy; cancer type; childhood sarcoma; clinical application; clinical decision-making; conventional therapy; drug sensitivity; ethnic minority; ethnic minority population; health disparity; health equity promotion; improved; individual patient; individualized medicine; infancy; minority children; minority patient; multiple omics; novel; novel therapeutics; patient population; pediatric patients; personalized cancer therapy; personalized intervention; personalized medicine; precision medicine; precision oncology; racial and ethnic; racial and ethnic disparities; racial diversity; racial minority; refractory cancer; relapse patients; response; survival outcome; targeted treatment; tool; transcriptomics; treatment disparity; treatment response

FIU-RCMI Research Project #1 Abstract Despite improvements in overall survival for pediatric cancers, treatment disparities remain for racial/ethnic minorities compared to non-Hispanic Whites. Black or Hispanic race/ethnicity are both significantly associated with decreased overall survival outcomes in childhood sarcomas, brain, and central nervous system tumors. Thus, there is a large unmet need for reducing racial/ethnic disparities to improve detection, treatment, and survival in pediatric cancer patients. It is well documented that Hispanic and Black children with cancer are more than 50 percent less likely to enroll in clinical trials testing cancer treatments than non-Hispanic White children. Particularly, studies that provide precision oncology approaches vastly underrepresent racial and ethnic minority populations. Thus, it is imperative to provide precision oncology studies that encompass children from diverse racial and ethnic backgrounds, so that meaningful precision data can be collected, and all individuals may benefit from cancer research breakthroughs and personalized treatments. We propose to address these problems by adopting, for the first time, a functional precision medicine (FPM) approach for individual minority patients to understand the genetic, molecular, transcriptomic, and phenotypic properties which may be particularly important for explaining Hispanic and Black cancer health disparities. We hypothesize that distinct genetic variance in Hispanic and Black populations is likely to substantially contribute to variability in drug treatment response and overall survival. Using our robust high throughput ex vivo drug sensitivity assay (DST), and combining it with mutation analysis, we will be able to create a compendium of drug responses in individual patients, match actionable mutations with selective targeted therapies, and clinically apply individual treatment to refractory patients with no alternative options. Hence, we propose the following aims: Specific Aim 1: To evaluate a functional precision medicine (FPM) approach as a tool to reduce cancer disparities in children. We intend to expand access of personalized treatment options and clinical management recommendations to Hispanic and Black pediatric cancer patients based on ex vivo drug sensitivity testing (DST) and genomic profiling. Specific Aim 2: To uncover novel correlations between genetic alterations and ex vivo drug responses in minority populations. We will perform multi-omics molecular profiling and integrate a machine learning platform to uncover novel relationships between molecular alterations and effective drugs specifically associated with Hispanic and Black pediatric populations. Our study will be the first of its kind to demonstrate the clinical utility of FPM to improve patient outcomes and reduce or eliminate the cancer disparities in Hispanic and Black children of South Florida. Our proposed work would also lead to identifying unique genetic and phenotypic properties associated with minority populations, providing opportunities for personalized interventions to promote health equity and more effective cancer treatments.

FIU-RCMI研究项目#1摘要 尽管儿童癌症的总体存活率有所改善，但种族/民族之间的治疗差异仍然存在。 少数族裔与非西班牙裔白人相比。黑人或西班牙裔种族/民族都与 儿童肉瘤、脑和中枢神经系统肿瘤的总体生存结果下降。 因此，有一个巨大的未得到满足的需求，即减少种族/民族差异，以改善发现、治疗和 儿童癌症患者的存活率。有充分的证据表明，患有癌症的西班牙裔和黑人儿童 参加测试癌症治疗的临床试验的可能性比非西班牙裔白人低50%以上 孩子们。特别是，提供精确肿瘤学方法的研究大大低估了种族和 少数民族人口。因此，必须提供涵盖以下内容的精确肿瘤学研究 来自不同种族和民族背景的儿童，以便能够收集有意义的准确数据，并且所有 个人可能受益于癌症研究的突破和个性化治疗。我们建议 通过首次采用功能精确医学(FPM)方法来解决这些问题 个别少数民族患者了解遗传、分子、转录和表型特性 这对于解释西班牙裔和黑人癌症的健康差异可能特别重要。我们 假设西班牙裔和黑人群体中不同的遗传变异可能对 药物治疗反应和总存活率的变异性。使用我们强大的高通量体外药物 敏感性分析(DST)，并将其与突变分析相结合，我们将能够创建一个概要 个体患者的药物反应，将可操作的突变与选择性靶向治疗相匹配，以及 临床上对没有其他选择的难治性患者进行个体化治疗。因此，我们建议 以下目标：具体目标1：评估功能精确医学(FPM)方法作为工具 减少儿童患癌症的差异。我们打算扩大个性化治疗选择的渠道，并 基于体外药物对西班牙裔和黑人儿童癌症患者的临床管理建议 敏感性测试(DST)和基因组图谱。具体目标2：揭示基因与基因之间的新关联 少数民族人群中的改变和体外药物反应。我们将进行多组学分子图谱分析 并集成了一个机器学习平台，以揭示分子变化和 专门针对西班牙裔和黑人儿科人群的有效药物。我们的研究将是第一个 以展示临床应用，以改善患者的预后，减少或消除 南佛罗里达州西班牙裔和黑人儿童的癌症差异。我们提议的工作还将导致 确定与少数群体相关的独特遗传和表型特征，提供 提供个性化干预的机会，以促进健康公平和更有效的癌症治疗。